Valeant returns fipamezole rights to Santhera

Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) returned rights in the U.S. and Canada to Santhera Pharmaceuticals Holding AG (SIX:SANN) for fipamezole ( JP-1730). Valeant gained rights to the program through its merger with Biovail Corp. this year, but decided not to continue the project after a review of the merged company's pipelines, according to Santhera. ...